CN Patent

CN112739338A — β-内酰胺化合物与丙磺舒的组合及其用途

Assigned to Italen Treatment International Ltd · Expires 2021-04-30 · 5y expired

What this patent protects

本公开涉及β‑内酰胺化合物或其药学上可接受的盐与丙磺舒或其药学上可接受的盐的组合。本公开还涉及经由向需要其的受试者给予β‑内酰胺化合物或其药学上可接受的盐和丙磺舒或其药学上可接受的盐来治疗或预防疾病的方法。

USPTO Abstract

本公开涉及β‑内酰胺化合物或其药学上可接受的盐与丙磺舒或其药学上可接受的盐的组合。本公开还涉及经由向需要其的受试者给予β‑内酰胺化合物或其药学上可接受的盐和丙磺舒或其药学上可接受的盐来治疗或预防疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN112739338A
Jurisdiction
CN
Classification
—
Expires
2021-04-30
Drug substance claim
No
Drug product claim
No
Assignee
Italen Treatment International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.